In short
MK-7262 is an investigational oral medicine being studied for elevated lipoprotein(a), a condition linked to a higher risk of heart disease. One authorised Phase 2 trial (2025-525102-38-00) is evaluating MK-7262 alone and together with enlicitide in 750 participants. The study measures changes in lipoprotein(a) and LDL cholesterol over 8 weeks, as well as side effects.
Key points
- MK-7262 is an investigational oral medicine studied for elevated lipoprotein(a).
- The only registered trial is a Phase 2 study with 750 participants.
- The trial is authorised but not yet recruiting.
- It tests MK-7262 alone and with enlicitide against placebo.
- Main outcomes include Lp(a) and LDL-C change at week 8 and adverse events.
- MK-7262 is taken orally.
What is MK-7262?
MK-7262 is an investigational oral medicine studied for elevated lipoprotein(a), also called Lp(a). The registry record for trial 2025-525102-38-00 lists MK-7262 as an intervention given by oral use. The trial also includes enlicitide (MK-0616) as a separate drug, with placebo arms for both substances. No marketing authorisation is mentioned in the provided data, so MK-7262 appears to be an investigational substance at this stage.
How does MK-7262 work?
The provided data do not describe the mechanism of action of MK-7262. The Phase 2 trial measures its effect on lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C), which suggests that the medicine is intended to lower these blood lipids. Lipoprotein(a) is a particle that carries cholesterol in the blood and is linked to a higher risk of heart disease.
Which conditions is MK-7262 studied for?
- Elevated lipoprotein(a) — a condition in which the level of lipoprotein(a) in the blood is higher than normal, which is associated with an increased risk of cardiovascular disease.
How is MK-7262 given?
MK-7262 is given by oral use, according to the trial record. The registry lists the intervention as a drug with a concentration of 00 % (V/V), which indicates that the exact dose or formulation strength was not reported in the register.
What do the clinical trials show?
One clinical trial of MK-7262 is registered in the EU Clinical Trials Information System. The trial, with identifier 2025-525102-38-00, is a Phase 2 interventional study with a planned enrollment of 750 participants. Its status is authorised, meaning the trial has received regulatory approval but is not yet recruiting or ongoing according to the register.
The study evaluates MK-7262 at four different dose levels, each tested alone and in combination with enlicitide. The primary outcomes are the percent change from baseline in lipoprotein(a) and LDL-C at week 8, the number of participants who experience one or more adverse events, and the number who discontinue the study intervention due to an adverse event. The trial aims to show whether MK-7262 alone or with enlicitide is superior to placebo in reducing Lp(a) and LDL-C.
What side effects are known?
The provided sources do not report any specific side effects of MK-7262. The Phase 2 trial includes safety outcomes, measuring the number of participants who experience one or more adverse events and the number who discontinue due to an adverse event.